BLUEBIRD BIO, INC.

Profile

Company Names

BLUEBIRD BIO, INC.
GENETIX PHARMACEUTICALS INC

Addresses

60 BINNEY STREET, CAMBRIDGE, MA 02142

840 MEMORIAL DR 4TH FL, CAMBRIDGE, MA 02139

840 MEMORIAL DR 3RD FL, CAMBRIDGE, MA 02139

Phone Numbers

339-499-9300
617-491-5601

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$187,477,264.00

Number of Funding Rounds:

4
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
4
2021-09-10 
$74,977,264.00 
$74,977,264.00 
$0.00 
Equity 
3
2012-07-23 
$60,000,000.00 
$60,000,000.00 
$0.00 
Equity 
2
2011-04-15 
$15,000,000.00 
$30,000,000.00 
$15,000,000.00 
Equity 
1
2010-03-05 
$37,500,000.00 
$37,500,000.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
JOHN 
 
AGWUNOBI 
DIRECTOR
BLUEBIRD BIO, INC.
CHIP 
 
BAIRD 
EXECUTIVE OFFICER
B. LANE, INC.   |  PWP GROWTH EQUITY FUND I LP   |  PWP GROWTH EQUITY FUND I (B) LP   |  MOD SUPER FAST PIZZA HOLDINGS, LLC   |  BBD HOLDCO LLC   |  DPN PARENT LLC   |  THEREALREAL, INC.   |  BLUEBIRD BIO, INC.   |  GREYLION CAPITAL FUND III B LP   |  GREYLION CAPITAL FUND III LP   |  GREYLION FUND III B LP   |  GREYLION FUND III LP
JASON 
 
COLE 
EXECUTIVE OFFICER
BLUEBIRD BIO, INC.
WENDY 
 
DIXON 
DIRECTOR
EDIMER PHARMACEUTICALS, INC.   |  BLUEBIRD BIO, INC.
JAMES 
A. 
GERAGHTY 
DIRECTOR
GENETIX PHARMACEUTICALS INC   |  ORCHARD THERAPEUTICS PLC   |  VOYAGER THERAPEUTICS, INC.
STEVEN 
 
GILLIS 
DIRECTOR
TRUBION PHARMACEUTICALS, INC   |  PHASERX INC   |  PULMATRIX INC   |  THERACLONE SCIENCES, INC.   |  MIRINA CORP   |  SURFACE LOGIX INC   |  ACYLIN THERAPEUTICS, INC.   |  BLUEBIRD BIO, INC.   |  VARIATION BIOTECHNOLOGIES (US), INC.   |  GROOVE BIOPHARMA CORP   |  ALLOZYNE INC   |  PHASERX, INC.   |  VIRAL LOGIC SYSTEMS TECHNOLOGY CORP   |  FARADAY PHARMACEUTICALS, INC.   |  PULMATRIX OPERATING COMPANY, INC.   |  LYCERA CORP   |  PULMATRIX, INC.   |  NEXGENIA INC.   |  CODIAK BIOSCIENCES, INC.   |  VBI VACCINES INC/BC   |  NOHLA THERAPEUTICS INC.   |  HOMOLOGY MEDICINES, INC.   |  IMMUSANT, INC.   |  ONCORESPONSE INC   |  EGENESIS, INC.   |  ARCH VENTURE FUND X, L.P.   |  ARCH VENTURE FUND X OVERAGE, L.P.   |  ARCH VENTURE FUND XI, L.P.   |  HC BIOSCIENCE, INC.   |  ARCH VENTURE FUND XII, L.P.   |  PHEAST THERAPEUTICS, INC.   |  SONOTHERA, INC.   |  PRONIRAS CORP   |  ONCORESPONSE, INC
RAMY 
 
IBRAHIM 
DIRECTOR
BLUEBIRD BIO, INC.   |  2SEVENTY BIO, INC.
NICK 
 
LESCHLY 
EXECUTIVE OFFICER, DIRECTOR
GENETIX PHARMACEUTICALS INC   |  BLUEBIRD BIO, INC.   |  PROCLARA BIOSCIENCES, INC.   |  SYNLOGIC, INC.   |  SYNLOGIC, INC.   |  2SEVENTY BIO, INC.   |  EDISON SCIENTIFIC, INC.
DANIEL 
S. 
LYNCH 
DIRECTOR
BLUEBIRD BIO, INC.   |  BIND BIOSCIENCES, INC   |  ELEVEN BIOTHERAPEUTICS, INC.   |  TRANSLATE BIO, INC.   |  SPRINGWORKS THERAPEUTICS, INC.
JOHN 
M. 
MARAGANORE 
DIRECTOR
BLUEBIRD BIO, INC.
GEERT-JAN 
 
MULDER 
DIRECTOR
TRANSAVE INC   |  GENETIX PHARMACEUTICALS INC   |  PROMEDIOR INC   |  EXOSOME THERANOSTICS, INC.   |  BLUEBIRD BIO, INC.   |  EXOSOME DIAGNOSTICS, INC.
AXEL 
 
POLACK 
DIRECTOR
GENETIX PHARMACEUTICALS INC   |  BLUEBIRD BIO, INC.
WILLIAM 
R. 
SELLERS 
DIRECTOR
BLUEBIRD BIO, INC.   |  2SEVENTY BIO, INC.
ROBERT 
 
TEPPER 
DIRECTOR
CERULEAN PHARMA INC.   |  ALNARA PHARMACEUTICALS INC   |  CONSTELLATION PHARMACEUTICALS INC   |  FOUNDATION MEDICINE, INC.   |  KALA PHARMACEUTICALS, INC.   |  BLUEBIRD BIO, INC.   |  THIRD ROCK VENTURES III, L.P.   |  ALLENA PHARMACEUTICALS, INC.   |  JOUNCE THERAPEUTICS, INC.   |  THIRD ROCK VENTURES IV, L.P.   |  NEON THERAPEUTICS, INC.   |  THIRD ROCK VENTURES V, L.P.   |  FAZE MEDICINES, INC.   |  THIRD ROCK VENTURES VI, L.P.
DENICE 
 
TORRES 
DIRECTOR
WYLEI, INC.   |  BLUEBIRD BIO, INC.   |  2SEVENTY BIO, INC.   |  SEAPORT THERAPEUTICS, INC.   |  BYHEART, INC.
MARK 
 
VACHON 
DIRECTOR
BLUEBIRD BIO, INC.
JEFFREY 
T. 
WALSH 
EXECUTIVE OFFICER
BLUEBIRD BIO, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2021-09-21
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2021-09-10 
2012-07-25
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-07-23 
2011-04-27
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2010-03-05 
2011-04-27
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2011-04-15 
2010-03-19
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2010-03-05 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#